Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

tolterodine (Rx)Brand and Other Names:Detrol, Detrol LA

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet, immediate release

  • 1mg
  • 2mg

capsule, extended release

  • 2mg
  • 4mg
more...

Overactive Bladder, Urge Incontinence

Immediate release: 2 mg PO q12hr

Extended release: 2-4 mg PO once daily

Dosing Modifications

Renal impairment

  • CrCl 10-30 mL/min: Not to exceed 1 mg PO q12hr (immediate release) or 2 mg PO once daily (extended release)
  • CrCl <10 mL/min: Not recommended

Hepatic impairment

  • Mild to moderate (Child-Pugh class A or B): Not to exceed 1 mg PO q12hr (immediate release) or 2 mg PO once daily (extended release)
  • Severe (Child-Pugh class C): Not recommended

Strong CYP3A4 inhibitors

  • Not to exceed 1 mg PO q12hr (immediate release) or 2 mg PO once daily (extended release)

Not recommended

Next

Interactions

Interaction Checker

tolterodine and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            >10%

            Dry mouth (40%)

            1-10%

            Blurred vision

            Constipation

            Dizziness

            Drowsiness

            Dyspepsia

            Headache

            Xerophthalmia

            Previous
            Next

            Warnings

            Contraindications

            Urinary or gastric retention

            Uncontrolled narrow-angle glaucoma

            Hypersensitivity to drug or ingredients or to fesoterodine fumarate, which is metabolized to 5-hydroxymethyl tolterodine

            Cautions

            Controlled narrow-angle glaucoma, bladder outflow obstruction, gastrointestinal obstruction, hepatic or renal impairment

            Anaphylaxis and angioedema necessitating hospitalization and emergency treatment reported with first or subsequent doses

            Anticholinergic central nervous system effects (eg, dizziness, somnolence) reported; patients should not drive or operate heavy machinery until they adjust to therapy

            Use with caution in patients with myasthenia gravis, which is characterized by decreased cholinergic activity at neuromuscular junction

            When coadministered with strong CYP3A4 inhibitors, tolterodine should be given at reduced dosage

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy category: C

            Lactation: Unknown whether drug is distributed in breast milk; do not nurse

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Competitive muscarinic receptor antagonist; decreases bladder contractions; is more specific for bladder than oxybutynin

            Absorption

            Bioavailability: 77%

            Onset: Overactive bladder, 1 wk; urge incontinence, 1 hr

            Time to peak effect: 2-4 wk

            Peak plasma time: Immediate release, 1-2 hr; extended release, 2-6 hr

            Distribution

            Vd: 113 L

            Metabolism

            Metabolized in liver by CYP2D6 and (to minor extent) CYP3A4

            Metabolites: 5-Hydroxymethyl, dealkylated tolterodine

            Elimination

            Half-life: Parent drug, 1.9-3.7 hr; active metabolite (5-hydroxymethyl), 3 hr (8.7 hr in cirrhosis)

            Total body clearance: 5.7 L/kg/hr

            Excretion: Urine (77%), feces (17%)

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.